Why the study?
The association between post-implant tricuspid regurgitation and heart failure hospitalization in patients without heart failure or preexisting abnormal tricuspid regurgitation and pressure gradient remained unclear.
Does progressive tricuspid regurgitation after transvenous permanent pacemaker implantation increase the risk of heart failure hospitalization in patients without preexisting heart failure?
Does progressive tricuspid regurgitation after transvenous permanent pacemaker implantation increase the risk of heart failure hospitalization in patients without preexisting heart failure?
Progressive tricuspid regurgitation occurs in 18.4% of patients after transvenous permanent pacemaker implantation and is associated with an increased risk of heart failure hospitalization.
Answers are grounded in this paper and cite their sources.
Progressive post-implant TR may signal higher HF hospitalization risk after PPM; hypothesis-generating and should not yet change practice.
Background The association of post-implant tricuspid regurgitation (TR) and heart failure (HF) hospitalization in patients without HF and preexisting abnormal TR and TR pressure gradient (PG) remain unclear. This study aimed to explore the clinical outcomes about progressive post-implant TR after permanent pacemaker (PPM) implantation. Methods A total of 1,670 patients who underwent a single ventricular or dual-chamber transvenous PPM implantation at our hospital between January 2003 and December 2017 were included in the study. Patients with prior valvular surgery, heart failure (HF), and baseline abnormal TR and TRPG were excluded. Finally, a total of 1,075 patients were enrolled in this study. Progressive TR was defined as increased TR grade of ≥2 degrees and/or TRPG of >30 mmHg after implant. Results 198 (18.4%) patients (group 1) experienced progressive post-implant TR and/or elevated TRPG, whereas 877 patients (group 2) did not have progressive post-implant TR. Group 1 had larger change in post-implant TRPG (group 1 vs. group 2; 12.8 ± 9.6 mmHg vs. 1.1 ± 7.6 mmHg; p < 0.001) than group 2. Group 1 had a higher incidence of HF hospitalization compared to group 2 (13.6% vs. 4.7%; p < 0.001). Pre-implant TRPG (HR: 1.075; 95% confidence interval (CI): 1.032-1.121; p = 0.001) was an independent predictor of progressive post-implant TR. Conclusions After a transvenous ventricular-based PPM implantation, 18.4% of patients experienced progressive post-implant TR and/or elevated TRPG. Higher pre-implant TRPG was an independent predictor of progressive post-implant TR.
No takes yet. Share an insight, caveat, or question.
Lee et al. (2020) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: